Want to see FR:ALTME full AI Analyst Report?
ALTME Stock Chart & Stats
€0.06
<€0.01(2.26%)
At close: 4:00 PM EST
€0.06
<€0.01(2.26%)
Day’s Range― - ―
52-Week Range€0.05 - €0.12
Previous CloseN/A
Volume26.06K
Average Volume (3M)547.76K
Market Cap
€6.94M
Enterprise Value€7.83M
Total Cash (Recent Filing)€2.02M
Total Debt (Recent Filing)€2.66M
Price to Earnings (P/E)―
Beta-0.36
Next Earnings
Oct 29, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.03
Shares Outstanding94,188,980
10 Day Avg. Volume795,319
30 Day Avg. Volume547,758
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-3.89
Price to Sales (P/S)0.00
P/FCF Ratio-1.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.15
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-stage PipelineTME Pharma's clear scientific focus on the tumor microenvironment and difficult-to-treat cancers (including brain tumors) is a durable strategic advantage. Specialization can create differentiated assets, attract targeted partnerships and grants, and improve chances of orphan or niche indications that sustain long-term value if clinical progress continues.
Lean Operating StructureA very small employee base implies a lean cost structure that can stretch limited capital farther than larger peers. For a pre-commercial biotech, disciplined headcount and outsourcing can materially extend runway, reduce fixed-cost drag, and make incremental financing more efficient over the coming funding cycles.
Prior Cash Burn ImprovementHistorical improvement in cash burn demonstrates management's ability to cut costs and optimize operations when needed. That operational discipline is a durable capability that can be redeployed to preserve runway, prioritize key trials, and manage dilution risk during future fundraising rounds.
Bears Say
Pre-commercial With No Meaningful RevenueThe absence of commercial revenue leaves TME Pharma reliant on external financing to fund R&D. Persistent operating losses mean the company cannot self-fund development, increasing dilution and execution risk; long-term viability hinges on successful trials or repeated capital raises.
Negative Equity And Rising DebtNegative shareholders' equity and a sharp debt increase in 2025 materially weaken solvency and financing flexibility. This structural balance-sheet stress raises refinancing and covenant risks, can increase funding costs, and limits strategic options for partnerships or licensing over the medium term.
Persistent Negative Cash Flow; 2025 DeteriorationConsistent negative operating and free cash flow, with deterioration in 2025, signals ongoing reliance on external capital and unstable burn dynamics. This structural cash-flow weakness shortens runway, increases fundraising frequency, and imposes execution risk on clinical programs and milestone delivery.
TME Pharma N.V. News
ALTME FAQ
What was TME Pharma N.V.’s price range in the past 12 months?
TME Pharma N.V. lowest stock price was €0.05 and its highest was €0.12 in the past 12 months.
What is TME Pharma N.V.’s market cap?
TME Pharma N.V.’s market cap is €6.94M.
When is TME Pharma N.V.’s upcoming earnings report date?
TME Pharma N.V.’s upcoming earnings report date is Oct 29, 2026 which is in 116 days.
How were TME Pharma N.V.’s earnings last quarter?
Currently, no data Available
Is TME Pharma N.V. overvalued?
According to Wall Street analysts TME Pharma N.V.’s price is currently Overvalued.
Does TME Pharma N.V. pay dividends?
TME Pharma N.V. does not currently pay dividends.
What is TME Pharma N.V.’s EPS estimate?
TME Pharma N.V.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does TME Pharma N.V. have?
TME Pharma N.V. has 94,188,980 shares outstanding.
What happened to TME Pharma N.V.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of TME Pharma N.V.?
Currently, no hedge funds are holding shares in FR:ALTME
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
TME Pharma N.V.
TME Pharma N.V., a biopharmaceutical company in the clinical development stage based in Berlin, Germany, is dedicated to pioneering innovative therapeutic solutions for cancer. The company leverages its unique Spiegelmer platform to advance a pipeline of investigational drug candidates. Its primary oncology asset, NOX-A12, is currently being evaluated in clinical studies as a combination therapy for a range of challenging cancers, including metastatic pancreatic and colorectal cancer, glioblastoma, and myeloma. Beyond its cancer-focused efforts, TME Pharma also developed NOX-E36, which has successfully concluded Phase 1/2 clinical trials for diabetic nephropathy. The company has formed a strategic collaboration with Merck Sharp & Dohme Corp. to explore NOX-A12 in combination with Keytruda and two different chemotherapy protocols as a second-line intervention for patients battling metastatic pancreatic cancer. Founded in 1997, the organization adopted its current name, TME Pharma N.V., in July 2022, having previously operated as NOXXON Pharma N.V.
Technical Analysis
Innate Pharma SA
―
Nanobiotix
―
Transgene
―
OSE Immunotherapeutics SA
―
Cellectis SA
―